Figure 1: Ruxolitinib exerts its anti-myeloma effects through several mechanisms. “[...] the results of the studies presented in this review will hopefully provide the impetus for conducting ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 trials.

JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

Medically reviewed by Mary Choy, PharmD Key Takeaways Biologic medications help reduce inflammation in ulcerative colitis. If you're new to biologics, infliximab might be your first option for ...

Prevalence of HRR gene mutations in patients with metastatic castration-resistant prostate cancer: Germline results from the Latin-American observational study PROSPECT. Using microfluidic models to ...

The JAK2 gene is a protein-coding gene of the Janus kinase family. It plays a role in cellular signaling. Evidence notes connections between this gene and some medical conditions. Variations in this ...

The future of dermatology is no longer just skin deep. This year’s American Academy of Dermatology (AAD) annual meeting was held March 7-11, 2025, in Orlando, FL, and it showcased the specialty’s ...

Please provide your email address to receive an email when new articles are posted on . The FDA has called for additional warning labels on janus kinase inhibitors after a safety review found this ...

Ruxolitinib cream is the first FDA-approved JAK inhibitor for skin repigmentation in people with vitiligo, paving the way for additional oral and topical JAK inhibitors to treat this autoimmune ...

A narrative review highlights flexible abrocitinib treatment for moderate-to-severe atopic dermatitis, emphasizing lowest ...